In vitro growth inhibition of human small cell lung cancer by physalaemin.
Production and secretion of neuroendocrine peptides by small cell lung cancer (SCLC) has been detected in the past years. Most recently the role of bombesin as an autocrine/paracrine growth modifier has been demonstrated. We used the soft agarose clonogenic assay to evaluate the influence of other neuroendocrine peptides on the in vitro proliferation of SCLC cell lines. Neuroendocrine peptides tested were adrenocorticotropic hormone, arginine vasopressin, calcitonin, glucagon, kassinin, neurotensin, physalaemin, somatostatin, and substance P. Experiments were carried out in serum-free and serum-supplemented media with and without serum-free incubation periods. Our results indicated that the amphibian undecapeptide physalaemin inhibits the clonal and mass culture growth of SCLC cell lines at picomolar concentrations. All other neuroendocrine peptides failed to influence SCLC growth in the test systems used. These results suggest a growth regulating effect of physalaemin and a potential new form of neuroendocrine peptide therapy for SCLC.
D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D001127:Arginine Vasopressin / Q000494:pharmacology; D002116:Calcitonin / Q000494:pharmacology; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002455:Cell Division / Q000187:drug effects; D005934:Glucagon / Q000494:pharmacology; D006801:Humans; D015286:Kassinin; D007705:Kinins / Q000627:therapeutic use*; D009496:Neurotensin / Q000494:pharmacology; D009842:Oligopeptides / Q000494:pharmacology; D010803:Physalaemin / Q000627:therapeutic use*; D013004:Somatostatin / Q000494:pharmacology; D013373:Substance P / Q000494:pharmacology
D007705:Kinins; D009842:Oligopeptides; D001127:Arginine Vasopressin; D010803:Physalaemin; D013373:Substance P; D009496:Neurotensin; D013004:Somatostatin; D015286:Kassinin; D000324:Adrenocorticotropic Hormone; D002116:Calcitonin; D005934:Glucagon